Publication date: Jan 07, 2021
The European Commission (EC) has approved a new intramuscular (IM) injection route of administration for Biogen’s Plegridy for the treatment of relapsing-remitting multiple sclerosis (RRMS).
The new IM route of administration, while still providing patients with the same efficacy and safety of Plegridy, has the potential for reduction in injection site reactions compared to SC administration, Biogen said in a statement.
Aside from MS, Biogen has high hopes for its potential Alzheimer’s disease therapy aducanumab, which is currently under review with the US Food and Drug Administration.
|disease||MESH||injection site reactions|
|disease||MESH||relapsing-remitting multiple sclerosis|